Repligen logged a -2.6% change during today's afternoon session, and is now trading at a price of $116.5 per share. The S&P 500 index moved 1.0%. RGEN's trading volume is 1,150,876 compared to the stock's average volume of 530,875.
Repligen trades -40.72% away from its average analyst target price of $196.54 per share. The 13 analysts following the stock have set target prices ranging from $165.0 to $240.0, and on average have given Repligen a rating of buy.
Anyone interested in buying RGEN should be aware of the facts below:
-
Repligen's current price is -91.7% below its Graham number of $1403.58, which implies the stock has a margin of safety
-
Repligen has moved -36.0% over the last year, and the S&P 500 logged a change of 9.0%
-
Based on its trailing earnings per share of 2.42, Repligen has a trailing 12 month Price to Earnings (P/E) ratio of 48.1 while the S&P 500 average is 15.97
-
RGEN has a forward P/E ratio of 50.9 based on its forward 12 month price to earnings (EPS) of $2.29 per share
-
The company has a price to earnings growth (PEG) ratio of -47.77 — a number near or below 1 signifying that Repligen is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.3 compared to its sector average of 4.16
-
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
-
Based in Waltham, the company has 2,025 full time employees and a market cap of $6.5 Billion.